Literature DB >> 18263705

Glucose and leptin induce apoptosis in human beta-cells and impair glucose-stimulated insulin secretion through activation of c-Jun N-terminal kinases.

Kathrin Maedler1, Fabienne T Schulthess, Christelle Bielman, Thierry Berney, Christophe Bonny, Marc Prentki, Marc Y Donath, Raphael Roduit.   

Abstract

c-Jun N-terminal kinases (SAPK/JNKs) are activated by inflammatory cytokines, and JNK signaling is involved in insulin resistance and beta-cell secretory function and survival. Chronic high glucose concentrations and leptin induce interleukin-1beta (IL-1beta) secretion from pancreatic islets, an event that is possibly causal in promoting beta-cell dysfunction and death. The present study provides evidence that chronically elevated concentrations of leptin and glucose induce beta-cell apoptosis through activation of the JNK pathway in human islets and in insulinoma (INS 832/13) cells. JNK inhibition by the dominant inhibitor JNK-binding domain of IB1/JIP-1 (JNKi) reduced JNK activity and apoptosis induced by leptin and glucose. Exposure of human islets to leptin and high glucose concentrations leads to a decrease of glucose-induced insulin secretion, which was partly restored by JNKi. We detected an interplay between the JNK cascade and the caspase 1/IL-1beta-converting enzyme in human islets. The caspase 1 gene, which contains a potential activating protein-1 binding site, was up-regulated in pancreatic sections and in isolated islets from type 2 diabetic patients. Similarly, cultured human islets exposed to high glucose- and leptin-induced caspase 1 and JNK inhibition prevented this up-regulation. Therefore, JNK inhibition may protect beta-cells from the deleterious effects of high glucose and leptin in diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18263705     DOI: 10.1096/fj.07-101824

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  35 in total

Review 1.  Minireview: Meeting the demand for insulin: molecular mechanisms of adaptive postnatal beta-cell mass expansion.

Authors:  Mira M Sachdeva; Doris A Stoffers
Journal:  Mol Endocrinol       Date:  2009-02-05

2.  Glucose-Induced β-Cell Dysfunction In Vivo: Evidence for a Causal Role of C-jun N-terminal Kinase Pathway.

Authors:  Christine Tang; Lucy Shu Nga Yeung; Khajag Koulajian; Liling Zhang; Kevin Tai; Allen Volchuk; Adria Giacca
Journal:  Endocrinology       Date:  2018-11-01       Impact factor: 4.736

Review 3.  JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease.

Authors:  Giovanni Tarantino; Armando Caputi
Journal:  World J Gastroenterol       Date:  2011-09-07       Impact factor: 5.742

4.  cJUN N-terminal kinase (JNK) activation mediates islet amyloid-induced beta cell apoptosis in cultured human islet amyloid polypeptide transgenic mouse islets.

Authors:  S L Subramanian; R L Hull; S Zraika; K Aston-Mourney; J Udayasankar; S E Kahn
Journal:  Diabetologia       Date:  2011-10-26       Impact factor: 10.122

Review 5.  Connecting type 1 and type 2 diabetes through innate immunity.

Authors:  Justin I Odegaard; Ajay Chawla
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

Review 6.  Helicobacter pylori infection and diabetes: is it a myth or fact?

Authors:  Cong He; Zhen Yang; Nong-Hua Lu
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

7.  Cocaine- and amphetamine-regulated transcript (CART) protects beta cells against glucotoxicity and increases cell proliferation.

Authors:  Ramasri Sathanoori; Björn Olde; David Erlinge; Olga Göransson; Nils Wierup
Journal:  J Biol Chem       Date:  2012-12-16       Impact factor: 5.157

8.  Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients.

Authors:  Gilberto Paz-Filho; Karin Esposito; Barry Hurwitz; Anil Sharma; Chuanhui Dong; Victor Andreev; Tuncay Delibasi; Halil Erol; Alejandro Ayala; Ma-Li Wong; Julio Licinio
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-10-14       Impact factor: 4.310

9.  Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study.

Authors:  Maren Carstensen; Christian Herder; Mika Kivimäki; Markus Jokela; Michael Roden; Martin J Shipley; Daniel R Witte; Eric J Brunner; Adam G Tabák
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

10.  Elimination of negative feedback control mechanisms along the insulin signaling pathway improves beta-cell function under stress.

Authors:  Diana Gurevitch; Sigalit Boura-Halfon; Roi Isaac; Galit Shahaf; Moti Alberstein; Denise Ronen; Eli C Lewis; Yehiel Zick
Journal:  Diabetes       Date:  2010-06-14       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.